Effect of talquetamab on responses in patients with relapsed and refractory multiple myeloma with prior exposure to T-cell directed therapies.
A Graeter, OA Castaneda Puglianini, DK Hansen… - 2024 - ascopubs.org
7524 Background: Talquetamab (Talq) is a GPRC5D and CD3 bispecific antibody approved
for use in RRMM in pts previously treated with at least 4 lines of therapy, including a PI, IMiD,
and CD38 monoclonal antibody. Data from the MonumenTAL-1 study showed an ORR of
63% at 11.8 median months of follow-up in pts previously receiving T-cell directed therapies
(TCDT). CRS was noted in 77% of pts, and ICANS in 3% of patients receiving TCDT. Here,
we present data further supporting the safety and efficacy of Talq in RRMM pts previously …
for use in RRMM in pts previously treated with at least 4 lines of therapy, including a PI, IMiD,
and CD38 monoclonal antibody. Data from the MonumenTAL-1 study showed an ORR of
63% at 11.8 median months of follow-up in pts previously receiving T-cell directed therapies
(TCDT). CRS was noted in 77% of pts, and ICANS in 3% of patients receiving TCDT. Here,
we present data further supporting the safety and efficacy of Talq in RRMM pts previously …
Effect of Talquetamab on Responses in Patients with Relapsed and Refractory Multiple Myeloma with Prior Exposure to T-Cell Redirecting Therapies
O Castaneda, DK Hansen, MA Vazquez-Martinez… - Blood, 2024 - Elsevier
Background: Talquetamab (Talq) is a GPRC5D and CD3 bispecific antibody approved for
use in relapsed/refractory multiple myeloma (RRMM) in patients previously treated with at
least four lines of therapy, including a proteasome inhibitor (PI), immunomodulatory drug
(IMiD), and CD38 monoclonal antibody. Data from the MonumenTAL-1 study showed an
overall response rate (ORR) of 63% at 11.8 months median follow-up in patients previously
receiving T-cell redirecting therapies (TCRT). Here, we present data further supporting the …
use in relapsed/refractory multiple myeloma (RRMM) in patients previously treated with at
least four lines of therapy, including a proteasome inhibitor (PI), immunomodulatory drug
(IMiD), and CD38 monoclonal antibody. Data from the MonumenTAL-1 study showed an
overall response rate (ORR) of 63% at 11.8 months median follow-up in patients previously
receiving T-cell redirecting therapies (TCRT). Here, we present data further supporting the …
以上显示的是最相近的搜索结果。 查看全部搜索结果